Tern increases investment portfolio with £175,000 stake in Sure Ventures

TERN

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things (IoT) technology businesses, has announced that the Company has invested £175,000 of its cash balance in new ordinary shares in Sure Ventures plc, which are to be issued as part of a placing to raise a total of approximately £275,000 undertaken by Sure Ventures.

For its cash consideration of £175,000, Tern will acquire 213,414 new ordinary shares in Sure Ventures at a price of 82 pence per new ordinary share.  The Placing Price equates to the mid-market closing price of Sure Ventures’ ordinary shares on 31 December 2024 and Tern’s participation in the Placing will provide Tern with an approximate 2.7% holding in Sure Ventures on admission of the Placing shares to trading on the London Stock Exchange on or around 8 January 2025.  Tern will have no restrictions on its ability to trade the Sure Ventures shares acquired in the Placing.

Sure Ventures is a venture capital fund which invests in early-stage software companies in the rapidly growing technology areas of Artificial Intelligence (AI), Augmented Reality (AR), Virtual Reality (VR) and IoT.  It is listed on the Specialist Fund Segment of the London Stock Exchange with a reported net asset value per share, as at 30 September 2024, of 139 pence and a market capitalisation of £6.27 million, as at 31 December 2024 prior to the announcement of the Placing.  Sure Ventures’ unaudited interim report and financial statements announced on 5 December 2024 reported an unaudited loss before taxation and after finance costs for the six months ended 30 September 2024 of £181,746 and unaudited total net assets as at 30 September 2024 of £10,614,533.

Sure Ventures’ principal investments are a 25.9% interest in Sure Valley Ventures Fund (“SVV1”) and an approximate 6% interest in Sure Valley Enterprise Capital Fund (“SVV2”).  Tern already has a direct 5.9% interest in SVV2.

The Tern directors believe that this investment in Sure Ventures will provide Tern with the following benefits:

·    Exposure to a complimentary portfolio of specialist technology businesses at an attractive discount to Sure Ventures’ current net asset value, in particular its interest in SVV1’s portfolio.

·    Provide Tern with increased diversity of exposure to specialist technology businesses at different stages of development to Tern’s current key portfolio companies, Device Authority, FundamentalVR and Talking Medicines.

·    Further enhance Tern’s existing relationship with SVV2 and the ability to leverage potential synergies between Tern’s portfolio companies and those held by SVV1 and SVV2.

·    Potentially provide income to Tern from any distributions undertaken by Sure Ventures following SVV1 and SVV2 portfolio exits, including liquidity events already announced by Sure Ventures.

Online Investor Presentation and Q&A Session

As previously announced, the Company will be hosting an online presentation and Q&A session at 5.30 p.m. GMT on Thursday 9 January 2025.

Presenting will be members of Tern’s management team and management from Tern’s portfolio companies Device Authority, FundamentalVR and Talking Medicines, together with a representative of Vortex IQ, a SVV2 portfolio company.  This session is open to all existing and prospective shareholders.  Those who wish to attend should register via the following link where they will be provided with access details:

https://us02web.zoom.us/webinar/register/WN_95cYxDkWQPqzY9IK-nLoUQ

Participants will have the opportunity to submit questions during the session, but questions are welcomed in advance and may be submitted prior to 3 p.m. GMT on 8 January 2025 to: [email protected].

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines targets better pharmaceutical launch results through message analysis

Talking Medicines' Message Resonance Score measures doctors' understanding of pharmaceutical messaging to help companies improve launch strategies.

Device Authority addresses security risks as AI takes control of physical machines

Device Authority's KeyScaler platform supports secure AI-driven automation by helping organisations authenticate connected machines, protect device identities and control access to physical equipment.

Talking Medicines examines factors influencing prescribing decisions

Talking Medicines explains how healthcare professional conversations, clinical considerations and treatment perceptions can provide pharmaceutical companies with deeper insight into prescribing intent beyond traditional campaign metrics.

What HCPs say could reveal prescribing intent

Talking Medicines is using AI to analyse HCP conversations and identify the clinical and practical factors that may influence prescribing intent.

AI control of machines raises new security questions

AI is gaining the ability to control physical equipment, but establishing that machines are genuine, authorised and secure will be an important part of making this technology safe to deploy.

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Search